Ishihara K
Dept. of Dermatology, National Cancer Center Hospital, Japan.
Gan To Kagaku Ryoho. 1995 Jan;22(1):23-7.
At present, the chemotherapeutic combinations for melanoma available are three regimens using DAV, PAV and CDV. Among of them, the DAV combination (dacarbazine, ACNU, vincristine) and PAV (peplomycin, ACNU, vincristine) are used as post-operative adjuvant therapy for stage II and III patients. Their aim is to prevent recurrence and prolong survival. For stage IV patients, the major therapeutic procedure is a CDV combination (cisplatin, dacarbazine, vindesine). Adoptive immunotherapy is almost always used for patients with distant metastases. They have shown comparable effects for metastatic lesion in the lymph nodes, mucous membrane, brain and lung. Excellent results were obtained in patients having skin metastases by intratumoral injection of interferon-beta. Studies on new drugs and their combinations must be undertaken for more effective treatment of malignant melanoma.
目前，可用于黑色素瘤的化疗联合方案有使用DAV、PAV和CDV的三种方案。其中，DAV联合方案（达卡巴嗪、阿糖胞苷、长春新碱）和PAV（培普利霉素、阿糖胞苷、长春新碱）用作II期和III期患者的术后辅助治疗。其目的是预防复发和延长生存期。对于IV期患者，主要治疗方案是CDV联合方案（顺铂、达卡巴嗪、长春地辛）。过继性免疫疗法几乎总是用于有远处转移的患者。它们对淋巴结、黏膜、脑和肺的转移病灶显示出相似的效果。通过瘤内注射干扰素-β，皮肤转移患者取得了优异的疗效。必须开展关于新药及其联合使用的研究，以便更有效地治疗恶性黑色素瘤。
